A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
9 January, 2025
Tour de Cure grants support two valuable TROG trials
9 January 2025: Two important TROG Cancer Research trials
7 January, 2025
GenesisCare Foundation $300,000 donation to support TROG work
7 January 2025: TROG Cancer Research is advancing vital
